x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Bio Report

Levine Media Group

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

science life sciences

All Episodes

29:51

A Bet that Myostatins Can Muscle Out Obesity

The Bio Report ·

2025/05/07

GLP-1 agonists have been a breakthrough for the treatment of obesity, a global problem with serious health risks. While the benefits of these therapies are seen as outweighing the risks, there have been some concerns about the loss of muscle mass, particularly in older people using these drugs. iBio is developing next-generation obesity therapies that may be able to be used in combination with GLP-1 agonists or by themselves. Its lead experimental therapy is a myostatin inhibitor, part of a class of

en

25:04

Making Whole-Eye Transplantation a Reality

The Bio Report ·

2025/04/30

At the end of 2024, the Advanced Research Projects Agency for Health awarded a team led by the University of Colorado Anschutz Medical Campus, and including the Foundation Fighting Blindness and six other research groups, up to $46 million to advance research to enable human eye transplants to restore vision in people who are blind. The goal of the project is to make whole eye transplantation a reality by 2030. We spoke to Kia Washington, the project’s principal investigator and professor of surgery

en

34:38

Synbio Companies Come to Grips with the One “Omic”...

The Bio Report ·

2025/04/23

Synthetic biology companies have faced a difficult few years as share prices have been battered and investment in the sector has waned. As investors and companies are readying to gather for the annual SynBioBeta conference in San Jose May 5 through 8, a new report from the bipartisan National Security Commission on Emerging Biotechnology warns that the United States is at risk of losing its leadership to China and is calling for a $15 billion investment into biotech over the next five years to

en

39:19

Searching for Safer Pain Medications

The Bio Report ·

2025/04/16

Until recently, treatments for both chronic and acute pain had been an area that went for decades without the development of innovative new treatments. South Rampart Pharma is seeking to develop safer and more effective pain management therapies that avoid the liver toxicity of acetaminophen, the kidney toxicity of NSAIDs, and the abuse potential of opioids. We spoke to Hernan Bazan, co-founder and CEO of South Rampart Pharma, about the need for new pain medicines, the company’s first-in-class

en

27:45

Bridging the Translational Divide in Healthcare AI

The Bio Report ·

2025/04/09

The Zimin Institute for AI Solutions in Healthcare, a joint initiative between the Zimin Foundation and the Technion – Israel Institute of Technology, is seeking to accelerate the integration of AI into the life sciences. Although it is pursuing a wide range of opportunities from precision medicine to therapeutic discovery, its primary focus is on addressing real-world problems and conducting translational research. We spoke to Shai Shen-Orr, director of the Zimin Institute for AI Solutions, about

en

29:10

Seeking Long-Term Pain Relief from a Drug-Free Injection

The Bio Report ·

2025/04/02

The search for non-opioid pain relievers opioids has focused on pharmaceutical alternatives including non-steroidal anti-inflammatories, antidepressants, and anticonvulsants. Brixton Biosciences is developing Neural Ice, an injectable frozen slurry that can degenerate nerves in targeted areas and provide pain relief for extended periods. The discovery capitalizes on unexpected findings about the effects of a fat-reducing cosmetic procedure. We spoke to Sameer Sabir, co-founder and CEO of Brixton

en

39:43

Engaging Hard-to-Target Receptors with Antibodies...

The Bio Report ·

2025/03/26

Antibodies have been powerful tools for inhibiting a targeted protein. Abalone Bio is pursuing a new class of antibody therapies called activating antibodies that can regulate cellular processes and restore their balance. One aspect that makes these rare antibodies attractive is that they can target previously undruggable G protein-coupled receptors, allowing them to treat diseases that have been hard to address. We spoke to Richard Yu, co-founder and CEO of Abalone Bio, about activating antibodies,

en

01:11:18

An Insider’s View of the Patent Fights that Shaped...

The Bio Report ·

2025/03/19

Jorge Goldstein trained for a career in molecular biology and biochemistry before becoming a patent attorney, a background that positioned him to help shape patent law for the biotech industry throughout his 40-year career. In his new book Patenting Life: Tales from the Front Lines of Intellectual Property and the New Biology, Goldstein offers a history of the biotech industry through the lens of the critical patent battles that shaped the landscape. We spoke to Goldstein, founder of the law firm

en

28:36

Restoring Balance to the Immune System in Allergic...

The Bio Report ·

2025/03/12

Eosinophilic esophagitis is a progressive allergic disease characterized by difficulty swallowing and gastric reflux. It results from an elevated number of inflammatory immune cells in the walls of the esophagus. If left untreated, it can cause long-term complications, including scarring and difficulty swallowing. Revolo Biotherapeutics is developing a synthetic peptide therapy that can potentially restore immune system homeostasis in EOE and other allergic diseases. We spoke to Woody Bryan,

en

32:09

Turning Natural Killers into Off-the-Shelf Therapies...

The Bio Report ·

2025/03/05

NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t trigger cytokine storms, a common reaction to CAR-T therapies that can cause a systemic inflammatory response that can range from flu-like symptoms to

en

29:28

Combining an Antibody and siRNA to Treat Hepatitis B

The Bio Report ·

2025/02/26

More than a decade after the approval of a curative therapy for hepatitis C, hepatitis B has proven more challenging to tackle. Vir Biotechnology, in collaboration with Alnylam Pharmaceuticals, is developing a promising combination approach that marries Vir’s monoclonal antibody tobivibart with Alnylam’s siRNA elebsiran. We spoke to Mark Eisner, chief medical officer of Vir, about hepatitis B, the company’s combination therapy in development with Alnylam, and its platform technologies for developing

en

22:20

Looking at the Promise of GLP-1 Agonists Beyond Obesity

The Bio Report ·

2025/02/19

While GLP-1 agonists have been all the rage in treating obesity, Coya Therapeutics sees potential for these therapies to address inflammatory diseases. In fact, Coya is developing its low-dose interleukin 2 in combination with several different agents. The belief is that its approach will address inflammation by targeting dysfunctional regulatory T cells. The company is pursuing multiple neurodegenerative conditions, as well as autoimmune and metabolic diseases. We spoke to Arun Swaminathan, CEO of

en

31:20

An Off-the-Shelf Cancer Vaccine Faces a Final...

The Bio Report ·

2025/02/12

Though cancer vaccines have been an area of great promise, in practice they have faced several challenges because of the heterogeneity of tumors, the ability of the tumor microenvironment to suppress the immune system, and the challenges of producing a strong and sustained T-cell response. OSE Immunotherapeutics’ off-the-shelf cancer vaccine Tedopi has shown promising results in a phase 3 study in patients with non-small cell lung cancer and the company is now conducting a confirmatory phase 3

en

08:54

A Nose for Attacking Cancer

The Bio Report ·

2025/02/05

One of the challenges in treating brain cancer and other diseases of the central nervous system is delivering therapeutics beyond the blood-brain barrier. NeOnc Technologies using a natural compound derived from essential oils in plants that not only can kill cancer cells, but can cross the blood-brain barrier. What’s more, it can transport other therapies as well. We spoke to Thomas Chen, founder and CEO of NeOnc, about brain cancer, how the blood-brain barrier complicates the delivery of therapies

en

24:52

An Unnatural Approach to Undruggable Targets

The Bio Report ·

2025/01/29

Some 70 percent of potential therapeutic targets are believed to be beyond the reach of conventional small molecule therapies or biologics. Macrocyclic peptides offer a way to get at elusive targets while providing desirable characteristics of both small molecule drugs and biologics. They offer oral bioavailability, can permeate cells, and engage complex targets with specificity. Unnatural Products is harnessing AI to create synthetic macrocyclic peptides to pursue previously undruggable targets. We

en

33:52

Expanding the Drug Developer’s Chemical Universe

The Bio Report ·

2025/01/22

Through the creation of a chemical programming language, Chemify said it has been able to expand the chemical space it can explore. Chemify is combining this unique programming language with robotics and AI to digitize chemistry. The company, though, has much grander ambitions than being a drug developer. It wants to be the infrastructure for the industry. We spoke to Lee Cronin, founder and CEO of Chemify, about the company’s platform technology for digitizing chemistry, how its chemical

en

29:20

Take 100 Megabytes a Day and Call Me in the Morning

The Bio Report ·

2025/01/15

Prescription digital therapies, the use of software to treat disease, are growing in number. Already there have been 140 prescription digital therapies that have been granted market access through national regulatory and reimbursement pathways. That represents a five-fold increase in the since 2021, according to the IQVIA Digital Health Trends 2024 report. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about the report, why digital health companies faced

en

34:25

Extracting the Benefits of Psychedelics

The Bio Report ·

2025/01/08

There has been growing interest in the potential of psychedelics to treat a variety of mental health conditions. While some focus has been put on synthesizing compounds that can target the receptors psychedelics bind to without inducing their hallucinatory effects, Filament Health is taking a notably different approach. The company, co-founded by Ben Lightburn who previously ran a firm specializing in natural extraction technologies, is focusing on developing pharmaceutical grade botanical drugs

en

37:40

A Magellan that Circumnavigates Active Binding Sites

The Bio Report ·

2025/01/01

Gain Therapeutics' platform technology Magellan leverages AI, structural biology, and physics-based models to identify novel binding sites on otherwise undruggable proteins implicated in diseases. The company’s experimental Parkinson’s disease therapy has the potential to slow or stop progression of the neurodegenerative condition by stabilizing a lysosomal enzyme implicated in the disease. We spoke to Gene Mack, CEO of Gain, about the company’s platform technology, how its experimental therapy for

en

40:28

A Very Meh-Ry Biotech Year and What’s Ahead in 2025

The Bio Report ·

2024/12/25

We continue our holiday tradition by welcoming STAT News Senior Biotech Writer Adam Feuerstein for our annual look back at the year that was in biotech and what’s ahead for the industry with the JPMorgan Healthcare conference and beyond in 2025. Feuerstein offers his view on finance and dealmaking in 2024, new drug approvals, and his annual take on the best and worst CEOs of the year. We also discuss what Trump 2.0 may look like for the industry, changes coming to the FDA and other agencies, and

en

305 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter